TY - JOUR
T1 - Effect of nonnicotine pharmacotherapy on smoking behavior
AU - Kotlyar, Michael
AU - Golding, Michael
AU - Hatsukami, Dorothy K.
AU - Jamerson, Brenda D.
PY - 2001
Y1 - 2001
N2 - Smoking-related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.
AB - Smoking-related disease is the single biggest preventable cause of morbidity and mortality in the United States, yet approximately 25% of Americans continue to smoke. Various dosage forms of nicotine replacement therapy increase smoking quit rates relative to placebo, but they generally do not result in 1-year quit rates of over 20%. To increase these rates, a number of nonnicotine agents have been investigated. Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters.
UR - http://www.scopus.com/inward/record.url?scp=0035212266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035212266&partnerID=8YFLogxK
U2 - 10.1592/phco.21.20.1530.34477
DO - 10.1592/phco.21.20.1530.34477
M3 - Review article
C2 - 11765304
AN - SCOPUS:0035212266
SN - 0277-0008
VL - 21
SP - 1530
EP - 1548
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 12
ER -